Literature DB >> 33746388

Arginase/nitric oxide modifications using live non-pathogenic Leishmania tarentolae as an effective delivery system inside the mammalian macrophages.

Alireza Badirzadeh1, Hossein Montakhab-Yeganeh2,3, Touraj Miandoabi4.   

Abstract

Recombinant live delivery system based on chemokine IFN-γ-inducible protein-10 kDa (CXCL 10 or IP-10), as a suitable immunotherapy tool, have been used for the treatment of Leishmania infections. This chemokine can defeat Leishmania spp. infection via producing nitric oxide (NO) for parasite killing. This study was performed to investigate the effects of IP-10 on the infected human macrophages by L. tarentolae expressing IP-10. We also quantified the arginase activity and NO production in the co-cultured human macrophages with L. tarentolae expressing IP-10 as compared with wild L. tarentolae. The results elucidate that in the infected cells with L. tarentolae expression of IP-10 the arginase activity decreased, and inversely, NO production intensely increased. Altogether, L. tarentolae expressing IP-10 shows a favorable therapeutic tool to improve the treatment of Leishmania infection. This work suggests that L. tarentolae expressing IP-10 cause specific effects on the metabolic pathways of the macrophage host, which might enable the host cells in killing of parasites and decreasing the survival of them against Leishmania infection. © Indian Society for Parasitology 2020.

Entities:  

Keywords:  Arginase activity; IP-10; Immunotherapy; Leishmania tarentolae; Leishmaniasis; Nitic oxide

Year:  2020        PMID: 33746388      PMCID: PMC7921220          DOI: 10.1007/s12639-020-01279-5

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  39 in total

1.  Differential expression of TLRs 2, 4, 9, iNOS and TNF-α and arginase activity in peripheral blood monocytes from glucantime unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis caused by Leishmania tropica.

Authors:  Razieh Tavakoli Oliaee; Iraj Sharifi; Ali Afgar; Abdollah Jafarzadeh; Amir Tavakoli Kareshk; Mehdi Bamorovat; Hamid Sharifi; Zahra Babaei; Amir Keyhani; Alireza Keyhani; Leili Abedi; Fatemeh Sharifi
Journal:  Microb Pathog       Date:  2018-11-03       Impact factor: 3.738

2.  Cytokine profile and nitric oxide levels in macrophages exposed to Leishmania infantum FML.

Authors:  Shafiei Reza; Namdar Ahmadabad Hasan; Nezafat Firizi Maryam; BakhshiJoibari Fahimeh; Amirali Ghahremani; Hatam GholamReza; Ghatee Mohammad Amin
Journal:  Exp Parasitol       Date:  2019-05-22       Impact factor: 2.011

Review 3.  Recombinant protein expression in Leishmania tarentolae.

Authors:  Giancarlo Basile; Manuela Peticca
Journal:  Mol Biotechnol       Date:  2009-11       Impact factor: 2.695

Review 4.  L-arginine metabolism and its impact on host immunity against Leishmania infection.

Authors:  Nanchaya Wanasen; Lynn Soong
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

5.  Leishmania major MPK7 protein kinase activity inhibits intracellular growth of the pathogenic amastigote stage.

Authors:  Miguel A Morales; Pascale Pescher; Gerald F Späth
Journal:  Eukaryot Cell       Date:  2009-10-02

6.  CXC chemokine-mediated protection against visceral leishmaniasis: involvement of the proinflammatory response.

Authors:  Gaurav Gupta; Surajit Bhattacharjee; Sandip Bhattacharyya; Parna Bhattacharya; Anupam Adhikari; Asok Mukherjee; Suchandra Bhattacharyya Majumdar; Subrata Majumdar
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

7.  Application of BisANS fluorescent dye for developing a novel protein assay.

Authors:  Zsolt Datki; Zita Olah; Lilla Macsai; Magdolna Pakaski; Bence Galik; Gabor Mihaly; Janos Kalman
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

Review 8.  Leishmania tarentolae: Taxonomic classification and its application as a promising biotechnological expression host.

Authors:  Stephan Klatt; Larry Simpson; Dmitri A Maslov; Zoltán Konthur
Journal:  PLoS Negl Trop Dis       Date:  2019-07-25

9.  Frequency of Cutaneous Leishmaniasis and Species Identification in Suspected Individuals from Golestan Province, Northern Iran in 2014.

Authors:  Farideh Hezari; Maryam Niyyati; Seyyed Javad Seyyed Tabaei; Mehdi Mohebali; Vahideh Moin Vaziri; Hamed Behniafar; Eznolah Azargashb; Niloofar Taghipour
Journal:  Iran J Public Health       Date:  2016-10       Impact factor: 1.429

10.  Molecular-Based Detection of Leishmania infantum in Human Blood Samples in a New Focus of Visceral Leishmaniasis in Lorestan Province, Iran.

Authors:  Leila Masoori; Farnaz Kheirandish; Ali Haghighi; Mehdi Mohebali; Behnaz Akhoundi; Niloofar Taghipour; Latif Gachkar; Ali Chegeni-Sharafi; Vahideh Moin-Vaziri
Journal:  J Arthropod Borne Dis       Date:  2018-03-18       Impact factor: 1.198

View more
  3 in total

1.  Bionomics and phylo-molecular analysis of Leishmania species isolated from human lesions using ITS1 genes in north-east of Iran.

Authors:  Reza Shafiei; Mohsen Kalantari; Masoud Yousefi; Ashok Aspatwar; Kourosh Arzamani; Arezoo Bozorgomid; Hadi Mirahmadi; Ali Soleimani; Saber Raeghi
Journal:  J Parasit Dis       Date:  2021-02-10

2.  Leishmania tarentolae as an Antigen Delivery Platform: Dendritic Cell Maturation after Infection with a Clone Engineered to Express the SARS-CoV-2 Spike Protein.

Authors:  Ilaria Varotto-Boccazzi; Micaela Garziano; Giulia Maria Cattaneo; Beatrice Bisaglia; Paolo Gabrieli; Mara Biasin; Alessandro Manenti; Diego Rubolini; Mario Clerici; Emanuele Montomoli; Gian Vincenzo Zuccotti; Daria Trabattoni; Sara Epis; Claudio Bandi
Journal:  Vaccines (Basel)       Date:  2022-05-19

3.  Effects of negative air ions (NAIs) on Leishmania major: A novel tool for treatment of zoonotic cutaneous leishmaniasis (ZCL).

Authors:  Alireza Badirzadeh; Mehdi Najm; Andrew Hemphill; Maryam Alipour; Hamid Hasanpour; Leila Masoori; Poorya Karimi
Journal:  PLoS One       Date:  2022-09-08       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.